Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
The Source
CNBC
Business
Cyclospora outbreak tests RFK Jr.’s promise to overhaul food system, rebuild trust in CDC
CNBC·55m ago·3 min read
US
Moonshot AI accessed Nvidia’s chips despite Chinese export ban, White House official says
CNBC·2h ago·3 min read
Business
Comcast earnings highlight NBCUniversal strength ahead of planned split
CNBC·2h ago·3 min read
US
IRS chief Frank Bisignano may have misled Congress, Democrats say
CNBC·2h ago·3 min read
Related
On this beat
Health
An outbreak of cyclosporiasis that’s sickened thousands shouldn’t prevent you from enjoying a Caesar salad—if you take the right precautions
TWSJ·28m ago·3 min read
Health
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
TWSJ·2h ago·3 min read
Health
Ozempic face? Botox maker reports boost from ‘sagging face’ trend
CNBC·2h ago·3 min read
Health
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
TNYT·4h ago·3 min read